We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DPI Announces Drug Discovery Collaboration with Mitsubishi Pharma
News

DPI Announces Drug Discovery Collaboration with Mitsubishi Pharma

DPI Announces Drug Discovery Collaboration with Mitsubishi Pharma
News

DPI Announces Drug Discovery Collaboration with Mitsubishi Pharma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DPI Announces Drug Discovery Collaboration with Mitsubishi Pharma "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Discovery Partners International, Inc., have announced that they have entered into a new drug discovery collaboration with Mitsubishi Pharma Corporation (Mitsubishi) to discover lead compounds for a therapeutic target selected by Mitsubishi.

DPI will make use of its comprehensive drug-like compound collection and leverage its expertise in assay development, high-throughput screening, and computational chemistry.

"We have had a successful history collaborating with Mitsubishi, and we are very pleased that Mitsubishi has decided to continue collaborating with Discovery Partners in a new target area," stated Riccardo Pigliucci, Chairman and CEO of Discovery Partners.

"This discovery collaboration serves as a strong testimony to our commitment to building long-term and value-added relationships with our pharmaceutical partners. The integrated drug discovery platform at DPI is enabled from target to optimized leads. Our collaboration model complements the needs of our partners to support any or all phases of the drug discovery process."

Advertisement